ICON Selected by the Biomarkers Consortium of the FNIH to Support Study Evaluating Variability in Insulin Secretory Parameters


Company News Release

ICON announced it has received a contract award from the Foundation for the National Institutes of Health (FNIH) to provide clinical support for the Biomarkers Consortium study entitled Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects.

ICON's metabolic research team will support the clinical execution of this project, including subject recruitment and testing in ICON's Clinical Pharmacology Unit, located in San Antonio, Texas.

The Biomarkers Consortium study aims to develop biomarkers that predict long-term beta cell function, particularly in response to an intervention or a new therapy for diabetes. Currently there is no accepted gold standard testing regimen for estimating beta cell function and many accepted regimens are technically complex, making them unsuitable for large, multi-center clinical studies. The study is one of a series

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.